Burggraaf J - Search Results

1

Interactions of sugammadex with various anticoagulants .

Kruithof AC, Kluft C, de Kam PJ, Laterveer GH, Moerland M, Burggraaf J. Kruithof AC, et al. Among authors: burggraaf j. Int J Clin Pharmacol Ther. 2020 Jul;58(7):395-403. doi: 10.5414/CP203733. Int J Clin Pharmacol Ther. 2020. PMID: 32383642

2

Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.

van Griensven JM, Koster RW, Burggraaf J, Huisman LG, Kluft C, Kroon R, Schoemaker RC, Cohen AF. van Griensven JM, et al. Among authors: burggraaf j. Clin Pharmacol Ther. 1998 Jan;63(1):39-47. doi: 10.1016/S0009-9236(98)90119-9. Clin Pharmacol Ther. 1998. PMID: 9465840

3

The oral bioavailability of pentosan polysulphate sodium in healthy volunteers.

Faaij RA, Srivastava N, van Griensven JM, Schoemaker RC, Kluft C, Burggraaf J, Cohen AF. Faaij RA, et al. Among authors: burggraaf j. Eur J Clin Pharmacol. 1999 Feb;54(12):929-35. doi: 10.1007/s002280050577. Eur J Clin Pharmacol. 1999. PMID: 10192753 Clinical Trial.

4

Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants.

Kemme MJ, Faaij RA, Schoemaker RC, Kluft C, Meijer P, Cohen AF, Burggraaf J. Kemme MJ, et al. Among authors: burggraaf j. Blood Coagul Fibrinolysis. 2001 Oct;12(7):583-91. doi: 10.1097/00001721-200110000-00012. Blood Coagul Fibrinolysis. 2001. PMID: 11685048

5

Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Kemme MJ, et al. Among authors: burggraaf j. Br J Clin Pharmacol. 2002 Dec;54(6):627-34. doi: 10.1046/j.1365-2125.2002.t01-1-01705.x. Br J Clin Pharmacol. 2002. PMID: 12492611 Free PMC article.

6

Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.

Kemme MJ, Schoemaker RC, Burggraaf J, van der Linden M, Noordzij M, Moerland M, Kluft C, Cohen AF. Kemme MJ, et al. Among authors: burggraaf j. J Pharmacokinet Pharmacodyn. 2003 Feb;30(1):3-22. doi: 10.1023/a:1023293325245. J Pharmacokinet Pharmacodyn. 2003. PMID: 12800805

7

Introduction to haemostasis from a pharmacodynamic perspective.

Kluft C, Burggraaf J. Kluft C, et al. Among authors: burggraaf j. Br J Clin Pharmacol. 2011 Oct;72(4):538-46. doi: 10.1111/j.1365-2125.2011.03946.x. Br J Clin Pharmacol. 2011. PMID: 21342216 Free PMC article. Review.

8

Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans.

Moerland M, Kemme M, Dijkmans A, Bergougnan L, Burggraaf J. Moerland M, et al. Among authors: burggraaf j. J Cardiovasc Pharmacol. 2011 Dec;58(6):575-80. doi: 10.1097/FJC.0b013e31822f6b8d. J Cardiovasc Pharmacol. 2011. PMID: 21822145 Clinical Trial.

9

Measurement of collagen- and serotonin-induced platelet aggregation in whole blood.

Moerland M, Kemme MJ, van der Linden M, Burggraaf J. Moerland M, et al. Among authors: burggraaf j. Expert Rev Clin Pharmacol. 2010 Mar;3(2):177-82. doi: 10.1586/ecp.10.2. Expert Rev Clin Pharmacol. 2010. PMID: 22111566

10

Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.

Kluft C, Meijer P, Kret R, Burggraaf J. Kluft C, et al. Among authors: burggraaf j. Int J Lab Hematol. 2013 Aug;35(4):379-84. doi: 10.1111/ijlh.12027. Epub 2012 Nov 14. Int J Lab Hematol. 2013. PMID: 23151091

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

306 results

Search Page

Filters